Navco Receives Health Canada Licence for Antimicrobial Nanosilver Skin Shield
Silver Nanoparticle Skin Shield Spray Receives Health Canada Natural Product License
Vancouver, British Columbia-(September 3, 2024) Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”), has received a Health Canada Natural Health Product licence (“NPN”) for its antibacterial - antimicrobial skin shield and wound spray. This is Navco’s first Health Canada product approval for a topical spray designed to help protect and cleanse against germs and to treat minor skin wounds and infections utilizing proprietary silver nanoparticle technology as its method of action.
Navco’s NPN-licensed topical spray cleanses and protects the skin against bacteria, microbes, viruses, fungi, and other pathogens. Navco’s silver nanoparticles destroy bacteria-microbes on contact and provide a longer-term barrier and protective coating to the skin. They are also effective with minor wounds, burns, and moisturizing and rejuvenating to the skin. The proprietary development of these silver nanoparticles results in significantly increased bioavailability and builds upon the wealth of knowledge associated with the benefits of novel methods of action using silver treatment. Navco’s antimicrobial spray is formulated with natural and known compounds, is alcohol free, is designed to minimize skin irritation and toxicity and to maximize healthy skin function.
“We are excited about bringing Navco’s innovative, proprietary, silver nanoparticle based alcohol-free skin care solutions to consumers. With an increasing awareness and concern over the impact that existing products can have on human skin, such as the significant rise in skin conditions like eczema, Navco’s antimicrobial skin shield product can offer a more effective and dermatologically friendly alternative”, said Marek Jasinski, COO of Navco Pharma. “We aim to meet the growing consumer demand for novel, enhanced, sustainable skincare and germ prevention solutions.”
About the Company
Navco is a Burlington, Ontario - based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, fungi, viruses, and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural known compounds and nanoparticles with a high degree of efficacy. Target markets include human health personal skin care, household institutional products and veterinary health.
For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize.
